Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8473 |
Intermediate Similarity |
NPD1091 |
Approved |
0.8467 |
Intermediate Similarity |
NPD1613 |
Approved |
0.8467 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8382 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.8299 |
Intermediate Similarity |
NPD1653 |
Approved |
0.8239 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.8175 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.8175 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.8105 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.8102 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8101 |
Intermediate Similarity |
NPD7054 |
Approved |
0.8058 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.805 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.805 |
Intermediate Similarity |
NPD7472 |
Approved |
0.8 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.795 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7926 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7901 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7895 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7875 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7812 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7755 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.773 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7718 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7714 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7702 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7683 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7681 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7681 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7677 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7613 |
Intermediate Similarity |
NPD37 |
Approved |
0.7609 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7606 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7595 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.758 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.758 |
Intermediate Similarity |
NPD4966 |
Approved |
0.758 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.758 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7578 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7578 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7578 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7574 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7554 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7552 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7534 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7534 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7534 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7517 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7517 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.75 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.75 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7484 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7465 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7452 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7444 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7431 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.741 |
Intermediate Similarity |
NPD3705 |
Approved |
0.741 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7407 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7405 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7397 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7397 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7365 |
Intermediate Similarity |
NPD5960 |
Phase 3 |
0.7365 |
Intermediate Similarity |
NPD5588 |
Approved |
0.7346 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7329 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7328 |
Intermediate Similarity |
NPD290 |
Approved |
0.732 |
Intermediate Similarity |
NPD7213 |
Phase 3 |
0.732 |
Intermediate Similarity |
NPD7212 |
Phase 2 |
0.7312 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7301 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7297 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.7296 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7286 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7273 |
Intermediate Similarity |
NPD7447 |
Phase 1 |
0.7266 |
Intermediate Similarity |
NPD1242 |
Phase 1 |
0.726 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7252 |
Intermediate Similarity |
NPD968 |
Approved |
0.7246 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7233 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7202 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7188 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7183 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7179 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7169 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.7153 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.7153 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7152 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7152 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7152 |
Intermediate Similarity |
NPD4675 |
Approved |
0.7152 |
Intermediate Similarity |
NPD4678 |
Approved |
0.7143 |
Intermediate Similarity |
NPD5846 |
Approved |
0.7143 |
Intermediate Similarity |
NPD5126 |
Approved |
0.7143 |
Intermediate Similarity |
NPD5125 |
Phase 3 |
0.7143 |
Intermediate Similarity |
NPD6516 |
Phase 2 |
0.7133 |
Intermediate Similarity |
NPD4108 |
Discontinued |
0.7133 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7126 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7125 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7124 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7123 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7118 |
Intermediate Similarity |
NPD8313 |
Approved |
0.7118 |
Intermediate Similarity |
NPD8312 |
Approved |
0.7111 |
Intermediate Similarity |
NPD228 |
Approved |
0.7105 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7099 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7097 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7097 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7081 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7078 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7075 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7073 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.707 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7063 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7051 |
Intermediate Similarity |
NPD5401 |
Approved |
0.7051 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7051 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7047 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7047 |
Intermediate Similarity |
NPD4340 |
Discontinued |
0.7037 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7034 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7019 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7019 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7019 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7019 |
Intermediate Similarity |
NPD2977 |
Approved |
0.7013 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7013 |
Intermediate Similarity |
NPD4535 |
Phase 3 |
0.7007 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7006 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD6653 |
Approved |
0.7 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.6993 |
Remote Similarity |
NPD2231 |
Phase 2 |
0.6993 |
Remote Similarity |
NPD2235 |
Phase 2 |
0.6987 |
Remote Similarity |
NPD6799 |
Approved |
0.6983 |
Remote Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.698 |
Remote Similarity |
NPD1558 |
Phase 1 |
0.6975 |
Remote Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.6974 |
Remote Similarity |
NPD6099 |
Approved |
0.6974 |
Remote Similarity |
NPD6100 |
Approved |
0.6968 |
Remote Similarity |
NPD2677 |
Approved |
0.6954 |
Remote Similarity |
NPD4978 |
Clinical (unspecified phase) |
0.6944 |
Remote Similarity |
NPD6583 |
Phase 3 |
0.6944 |
Remote Similarity |
NPD3685 |
Discontinued |
0.6944 |
Remote Similarity |
NPD6582 |
Phase 2 |
0.6934 |
Remote Similarity |
NPD5535 |
Approved |
0.6933 |
Remote Similarity |
NPD6355 |
Discontinued |
0.6932 |
Remote Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.6928 |
Remote Similarity |
NPD5763 |
Approved |
0.6928 |
Remote Similarity |
NPD3540 |
Phase 1 |
0.6928 |
Remote Similarity |
NPD5762 |
Approved |
0.6923 |
Remote Similarity |
NPD7680 |
Approved |
0.6914 |
Remote Similarity |
NPD7089 |
Clinical (unspecified phase) |
0.6913 |
Remote Similarity |
NPD4062 |
Phase 3 |
0.6909 |
Remote Similarity |
NPD5494 |
Approved |
0.6908 |
Remote Similarity |
NPD7033 |
Discontinued |
0.6903 |
Remote Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.6903 |
Remote Similarity |
NPD3892 |
Phase 2 |
0.6897 |
Remote Similarity |
NPD3225 |
Approved |
0.6892 |
Remote Similarity |
NPD3179 |
Approved |
0.6892 |
Remote Similarity |
NPD3180 |
Approved |
0.6883 |
Remote Similarity |
NPD2424 |
Discontinued |
0.6879 |
Remote Similarity |
NPD4357 |
Discontinued |
0.6875 |
Remote Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.6867 |
Remote Similarity |
NPD5837 |
Clinical (unspecified phase) |
0.6867 |
Remote Similarity |
NPD2238 |
Phase 2 |
0.6867 |
Remote Similarity |
NPD3620 |
Phase 2 |
0.6867 |
Remote Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.6867 |
Remote Similarity |
NPD4140 |
Approved |
0.6863 |
Remote Similarity |
NPD1551 |
Phase 2 |
0.6863 |
Remote Similarity |
NPD2796 |
Approved |
0.6863 |
Remote Similarity |
NPD3539 |
Phase 1 |
0.6859 |
Remote Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.6857 |
Remote Similarity |
NPD6843 |
Phase 3 |
0.6857 |
Remote Similarity |
NPD6841 |
Approved |
0.6857 |
Remote Similarity |
NPD6842 |
Approved |
0.6853 |
Remote Similarity |
NPD3496 |
Discontinued |
0.6839 |
Remote Similarity |
NPD3060 |
Approved |
0.6839 |
Remote Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.6835 |
Remote Similarity |
NPD4123 |
Phase 3 |
0.6835 |
Remote Similarity |
NPD3536 |
Discontinued |
0.6835 |
Remote Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.6831 |
Remote Similarity |
NPD5585 |
Approved |
0.6829 |
Remote Similarity |
NPD7768 |
Phase 2 |
0.6828 |
Remote Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.6821 |
Remote Similarity |
NPD230 |
Phase 1 |
0.6818 |
Remote Similarity |
NPD291 |
Approved |
0.6818 |
Remote Similarity |
NPD1375 |
Discontinued |
0.6815 |
Remote Similarity |
NPD1358 |
Approved |
0.6809 |
Remote Similarity |
NPD5536 |
Phase 2 |
0.6797 |
Remote Similarity |
NPD1510 |
Phase 2 |
0.6795 |
Remote Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.6795 |
Remote Similarity |
NPD7466 |
Approved |
0.6783 |
Remote Similarity |
NPD1778 |
Approved |
0.6776 |
Remote Similarity |
NPD3054 |
Approved |
0.6776 |
Remote Similarity |
NPD3052 |
Approved |
0.677 |
Remote Similarity |
NPD4005 |
Discontinued |
0.6763 |
Remote Similarity |
NPD7549 |
Discontinued |
0.6761 |
Remote Similarity |
NPD1182 |
Approved |
0.6759
|
Remote Similarity |
NPD1608 |
Approved |